Literature DB >> 2338269

Agalactosyl IgG in inflammatory bowel disease: correlation with C-reactive protein.

R Dubé1, G A Rook, J Steele, R Brealey, R Dwek, T Rademacher, J Lennard-Jones.   

Abstract

The proportion of oligosaccharide chains on the Fc fragment of IgG which terminate with N-acetylglucosamine (GlcNAc) rather than galactose is increased in rheumatoid arthritis and tuberculosis, and in sera from patients with Crohn's disease, probably because of decreased activity of a galactosyltransferase in B lymphocytes. We have assayed the prevalence of agalactosyl oligosaccharides on IgG in sera from 67 patients with inflammatory bowel disease (32 ulcerative colitis and 35 Crohn's disease). The prevalence of agalactosyl IgG significantly increases in the majority of Crohn's patients (19/35 patients), and correlates with the level of C-reactive protein (r = 0.79), and inversely with the concentration of serum albumin. Sera from ulcerative colitis patients show less frequent (nine of 32) and less marked rises in agalactosyl IgG, and sera with high C-reactive protein values can contain normal levels. Thus in ulcerative colitis no correlation was seen between the two assays. The diseases in which the percentage of agalactosyl IgG is raised (rheumatoid arthritis, tuberculosis, Crohn's disease and some ulcerative colitis) are characterised by simultaneous T cell mediated granulomatous tissue damage, and acute phase responses. Levels are normal in less tissue damaging granulomatous conditions, including sarcoidosis, and leprosy (except during episodes of erythema nodosum leprosum). We suggest therefore that a raised percentage of agalactosyl IgG is a correlate of a particular type of T cell mediated pathology which may be relevant to the pathogenesis of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2338269      PMCID: PMC1378418          DOI: 10.1136/gut.31.4.431

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

Review 1.  Rheumatoid arthritis, mycobacterial antigens and agalactosyl IgG.

Authors:  G A Rook
Journal:  Scand J Immunol       Date:  1988-10       Impact factor: 3.487

Review 2.  The role of IgG glycoforms in the pathogenesis of rheumatoid arthritis.

Authors:  T W Rademacher; R B Parekh; R A Dwek; D Isenberg; G Rook; J S Axford; I Roitt
Journal:  Springer Semin Immunopathol       Date:  1988

Review 3.  Role of activated macrophages in the immunopathology of tuberculosis.

Authors:  G A Rook
Journal:  Br Med Bull       Date:  1988-07       Impact factor: 4.291

4.  A comparative analysis of disease-associated changes in the galactosylation of serum IgG.

Authors:  R Parekh; D Isenberg; G Rook; I Roitt; R Dwek; T Rademacher
Journal:  J Autoimmun       Date:  1989-04       Impact factor: 7.094

5.  A monoclonal antibody raised by immunising mice with group A streptococci binds to agalactosyl IgG from rheumatoid arthritis.

Authors:  G A Rook; J Steele; T Rademacher
Journal:  Ann Rheum Dis       Date:  1988-03       Impact factor: 19.103

6.  A transient rise in agalactosyl IgG correlating with free interleukin 2 receptors, during episodes of erythema nodosum leprosum.

Authors:  E Filley; A Andreoli; J Steele; M Waters; D Wagner; D Nelson; K Tung; T Rademacher; R Dwek; G A Rook
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

7.  Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages.

Authors:  C Moreno; J Taverne; A Mehlert; C A Bate; R J Brealey; A Meager; G A Rook; J H Playfair
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

8.  An inexpensive, portable, battery-operated photometer for the reading of ELISA tests in microtitration plates.

Authors:  G A Rook; C H Cameron
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

9.  Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon.

Authors:  S J Hopkins; A Meager
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

10.  Age-related galactosylation of the N-linked oligosaccharides of human serum IgG.

Authors:  R Parekh; I Roitt; D Isenberg; R Dwek; T Rademacher
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

View more
  39 in total

Review 1.  Extracellular enzymes with immunomodulating activities: variations on a theme in Streptococcus pyogenes.

Authors:  Mattias Collin; Arne Olsén
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

Review 2.  The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Authors:  Sybille Böhm; Inessa Schwab; Anja Lux; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

Review 3.  Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future.

Authors:  Luca Cantarini; Donato Rigante; Antonio Vitale; Salvatore Napodano; Lazaros I Sakkas; Dimitrios P Bogdanos; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

Review 4.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Authors:  Inessa Schwab; Falk Nimmerjahn
Journal:  Nat Rev Immunol       Date:  2013-02-15       Impact factor: 53.106

Review 5.  Molecular basis for downregulation of C5a-mediated inflammation by IgG1 immune complexes in allergy and asthma.

Authors:  Manoj Kumar Pandey
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

6.  Glycosylation of IgG during potentially arthritogenic lentiviral infections.

Authors:  J McCulloch; Y W Zhang; M Dawson; G D Harkiss; E Peterhans; H R Vogt; P M Lydyard; G A Rook
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

Review 7.  Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?

Authors:  Michaela Seeling; Christin Brückner; Falk Nimmerjahn
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

8.  Is IgG galactosylation the relevant factor for pregnancy-induced remission of rheumatoid arthritis?

Authors:  Frauke Förger; Monika Ostensen
Journal:  Arthritis Res Ther       Date:  2010-02-24       Impact factor: 5.156

9.  Change in relative mobility of M protein following neuraminidase treatment in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Yuriko Kurihara; Shiro Iijima; Kouhei Fukushima; Toshiaki Hosaka; Kiyoko Shiba
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

10.  Serum immunoglobulin G reactive with endothelial cells in inflammatory bowel disease.

Authors:  A M Sawyerr; B E Pottinger; C O Savage; N J Bradley; M Hudson; A J Wakefield; J D Pearson; R E Pounder
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.